D
쿼드메디슨
464490KOSDAQ38.5 / 100
Reference Date: 2026-09-08
Financial Score14.0 / 40
News Sentiment12.5 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 20.1% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
QuadMedison develops next-generation drug delivery systems using micro needle platform technology, expanding its business through Contract Development and Manufacturing Organization (CDMO) agreements with pharmaceutical companies. The company's core technologies, including S-MAP, C-MAP, and P-MAP, enhance medication compliance and offer innovative solutions for vaccines and synthetic pharmaceuticals.
Number of Employees
90people
Average Salary
51.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
1.83Industry Average 1.201.0Point
1.5x industry avg (risky)
ROE
-32.69Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
31.04Industry Average 100.006.5Point
Half of industry avg (excellent)
Trend 2024~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲15.0% (1-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼43.5% (1-year basis)
ROE Trend
0.0 / 4
Avg ROE -40.5% (improving, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 4,915Won52-week high 24,55052-week low 4,870
1-month return0.0Point
1m -20.08% (strong drop)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
4 totalPositive 0Neutral 4Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-31
- Neutral[기재정정]임원ㆍ주요주주특정증권등소유상황보고서2026-08-31
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-31
- Neutral반기보고서 (2026.06)2026-08-13